REPRISE China - Clinical Evaluation in China

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety and effectiveness of the Lotus Edge™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic Chinese patients with calcific, severe native aortic stenosis who are considered at high risk for surgical valve replacement.

Detailed Description
-----------------
A independent Clinical Events Committee (CEC) will adjudge the safety endpoint. Subject has a documented aortic annulus size of ≥20 mm and ≤27 mm based on the center's assessment of pre-procedure diagnostic imaging (and confirmed by the Case Review Committee [CRC]). Monitor will review the source data regularly to compare the EDC to ensure the data entry can be accuracy, completeness, or representativeness. Will recruit maximum 62 subjects in maximum 6 sites Boston Scientific's Standard Operating Procedures to address operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management.

Official Title
-----------------
REPRISE China: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Edge™ Valve System - Clinical Evaluation in China

Conditions
-----------------
Stenoses, Aortic Valve

Intervention / Treatment
-----------------
* Device: Lotus Edge™ Valve System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 70 years. Subject has documented calcific, severe native aortic stenosis with an initial AVA of <1.0 cm2 (or AVA index of <0.6 cm2/m2), and a mean pressure gradient ≥40 mm Hg or jet velocity ≥4.0 m/s or doppler velocity index ≤0.25, as measured by echocardiography and/or invasive hemodynamics. Subject has a documented aortic annulus size of ≥20 mm and ≤27 mm based on the center's assessment of pre-procedure diagnostic imaging (and confirmed by the Case Review Committee [CRC]). Subject has symptomatic aortic valve stenosis with NYHA Functional Class ≥ II. There is agreement by the heart team (which must include a site investigator interventionalist and a site investigator cardiac surgeon) that subject is at high operative risk for surgical valve replacement (see note below for definition of high risk, the required level of surgical assessment, and CRC confirmation) and that TAVR is appropriate. Additionally, subject has at least one of the following. Society of Thoracic Surgeons (STS) score ≥ 8% -OR- If STS < 8%, subject has at least one of the following conditions: Hostile chest Porcelain aorta Severe pulmonary hypertension (> 60 mmHg) Prior chest radiation therapy Coronary artery bypass graft(s) at risk with re-operation Severe lung disease (need for supplemental oxygen, FEV1 < 50% of predicted, DLCO < 60%, or other evidence of severe pulmonary dysfunction) Neuromuscular disease that creates risk for mechanical ventilation or rehabilitation after surgical aortic valve replacement Orthopedic disease that creates risk for rehabilitation after surgical aortic valve replacement Childs Class A or B liver disease (subjects with Childs Class C disease are not eligible for inclusion in this trial) Frailty as indicated by at least one of the following: 5-meter walk > 6 seconds, Katz ADL score of 3/6 or less, body mass index < 21, wheelchair bound, unable to live independently Age ≥ 90 years Other evidence that subject is at high risk for surgical valve replacement (CRC must confirm agreement with site heart team that subject meets high risk definition) Heart team (which must include a cardiac interventionalist and an experienced cardiac surgeon) assessment that the subject is likely to benefit from valve replacement. Subject (or legal representative) understands the study requirements and the treatment procedures, and provides written informed consent Subject, family member, and/or legal representative agree(s) and subject is capable of returning to the study hospital for all required scheduled follow up visits. Exclusion Criteria: Subject has a congenital unicuspid aortic valve or Sievers Type 2 bicuspid aortic valve. Subject has had an acute myocardial infarction within 30 days prior to the index procedure (defined as Q-wave MI or non-Q-wave MI with total CK elevation ≥ twice normal in the presence of CK-MB elevation and/or troponin elevation). Subject has had a cerebrovascular accident or transient ischemic attack within the past 6 months prior to study enrollment. Subject has end-stage renal disease or has serum creatinine > 3mg/dl or has creatinine clearance rate <45ml/min. Subject has a pre-existing prosthetic aortic or mitral valve. Subject has severe (4+) aortic, tricuspid, or mitral regurgitation. Subject has a need for emergency surgery for any reason. Subject has a history of endocarditis within 6 months of index procedure or evidence of an active systemic infection or sepsis. Subject has echocardiographic evidence of new intra-cardiac vegetation or intraventricular or paravalvular thrombus requiring intervention. Subject has platelet count < 50,000 cells/mm3 (50×109/L) or > 700,000 cells/mm3 (700×109/L), or white blood cell count < 1,000 cells/mm3 (1×109/L). Subject requires chronic anticoagulation therapy after the implant procedure and cannot be treated with warfarin (other anticoagulants are not permitted in the first month) for at least 1 month concomitant with either aspirin or clopidogrel. Subject has had a gastrointestinal bleed requiring hospitalization or transfusion within the past 3 months, or has other clinically significant bleeding diathesis or coagulopathy that would preclude treatment with required antiplatelet regimen, or will refuse transfusions Subject has known hypersensitivity to contrast agents that cannot be adequately pre-medicated, or has known hypersensitivity to aspirin, all P2Y12 inhibitors, heparin, nickel, tantalum, titanium, or polyurethanes Subject has a life expectancy of less than 12 months due to non-cardiac, comorbid conditions based on the assessment of the investigator at the time of enrollment Subject has hypertrophic obstructive cardiomyopathy Subject has any therapeutic invasive cardiac or vascular procedure within 30 days prior to the index procedure (except for balloon aortic valvuloplasty or pacemaker implantation, which is allowed) Subject has untreated coronary artery disease, which in the opinion of the treating physician is clinically significant and requires revascularization Subject has severe left ventricular dysfunction with ejection fraction < 20% Subject is in cardiogenic shock or has hemodynamic instability requiring inotropic support or mechanical support devices Subject has severe vascular disease that would preclude safe access (e.g., aneurysm with thrombus that cannot be crossed safely, marked tortuosity, significant narrowing of the abdominal aorta, severe unfolding of the thoracic aorta, or symptomatic carotid or vertebral disease) Subject has thick (> 5 mm) protruding or ulcerated atheroma in the aortic arch Subject has an enlarged ascending aorta with the diameter > 50mm Subject has arterial access that is not acceptable for the study device delivery system as defined in the device Instructions For Use Subject has current problems with substance abuse (e.g., alcohol, etc.) Subject is participating in another investigational drug or device study that has not reached its primary endpoint Subject has untreated conduction system disorder (e.g., Type II second degree atrioventricular block) that in the opinion of the treating physician is clinically significant and requires a pacemaker implantation. Enrollment is permissible after permanent pacemaker implantation Subject has severe incapacitating dementia

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lotus Edge™ Valve System<br>The Lotus Edge™ Valve System is intended to improve the aortic valve function for symptomatic patients with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement. | Device: Lotus Edge™ Valve System<br>* • The Lotus Edge™ Valve System consisting of two main components: a bioprosthetic bovine pericardial aortic valve, and a delivery system Device sizes include 23 mm, 25 mm and 27 mm diameter.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | All-cause mortality through 30 days post index procedure. | Through 30 days post index procedure | 
| Mean aortic valve pressure gradient | Mean aortic valve pressure gradient at 30 days post index procedure. | At 30 days post index procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
High risk for surgical valve replacement, transcatheter aortic valve replacement